Sanofi Withdraws Teplizumab from FDA Fast-Track Review Amid Internal Disagreements

Sanofi has taken the step of asking the FDA to remove teplizumab from its fast-track review program. This decision appears to stem from internal disagreements within the company.

The request comes after a political appointee expressed differing views from FDA staff regarding the approval of the drug.

This development highlights the complexities and challenges that can arise in the drug approval process, particularly when there are conflicting opinions within a company.